Join the waitlistJoin

A traceable intelligence layer for the life sciences.

Myelin links companies, assets, targets, diseases and trials into one knowledge graph. Teams can deploy agents that run on it and automate recurring workflows, with a source for every claim.

Join the waitlist See the agents

Our pilot starts soon.

Catalyst CalendarIllustrative digest · Monday 8:00am

New retatrutide data is out. Petosemtamab Phase 3 readout expected this quarter.

  • Lilly reports TRIUMPH-2: 12 mg retatrutide, 20.8% average weight loss over 80 weeks in obesity with type 2 diabetes.

    Lilly press release, Sept. 29, 2026

  • Phase 3 readout expected for petosemtamab in first-line head and neck cancer in Q4 2026.

    Genmab Q2 2026 results presentation, Aug. 6, 2026

  • Lilly plans to submit a BLA for retatrutide to the FDA in Q1 2027.

    Lilly Q2 2026 results, Aug. 5, 2026

Illustrative digest shown as an example; not medical or investment advice.

Principles

  • Rapid

    Deploy an agent in one click. It runs on a schedule and flags what changed since its last run.

  • Sovereign

    Your files, questions, and outputs live in your organization’s private workspace. We don’t share them with other customers.

  • Traceable

    Every claim and number cites the file or source it came from, so you can check it yourself.

  • Complete

    Ask for every asset in an indication. You get every match we find, a count, and a reason for any candidate we left out. Counts are calculated from the underlying records.

One graph behind every agent

Sample view of petosemtamab with its combination partners, head-to-head comparators and same-indication competitors. Examples on this page are for illustration only and are not medical or investment advice.

  • Combination partner
  • Head-to-head
  • Same indication

Drag to rotate · hover a drug to isolate its links · Ctrl/Cmd + scroll to zoomDrag sideways to rotate · tap a drug to isolate its links

  • Petosemtamab (GMAB): combo · HN1 with Pembrolizumab; comparator · CRC1/2 · HN2 with Cetuximab; comparator · CRC2 with Bevacizumab; competes · 1L with Ficerafusp alfa; competes · 1L & 2L+ with Amivantamab SC; competes with Panitumumab; same indication · mCRC with Fruquintinib; same indication · mCRC with Zanzalintinib.
  • Pembrolizumab (MRK): combo · HN1 with Petosemtamab; combo · FORTIFI with Ficerafusp alfa; combo · OrigAMI-5 with Amivantamab SC.
  • Ficerafusp alfa (BCAX): competes · 1L with Petosemtamab; combo · FORTIFI with Pembrolizumab.
  • Amivantamab SC (JNJ): competes · 1L & 2L+ with Petosemtamab; combo · OrigAMI-5 with Pembrolizumab.
  • Cetuximab (LLY / Merck KGaA): comparator · CRC1/2 · HN2 with Petosemtamab.
  • Bevacizumab (ROG): comparator · CRC2 with Petosemtamab.
  • Panitumumab (AMGN): competes with Petosemtamab.
  • Fruquintinib (TAK): same indication · mCRC with Petosemtamab.
  • Zanzalintinib (EXEL): same indication · mCRC with Petosemtamab; combo · STELLAR-303 with Atezolizumab.
  • Atezolizumab (ROG): combo · STELLAR-303 with Zanzalintinib.

How it works

  1. Sources

    Public trial registries such as ClinicalTrials.gov and EU CTIS, FDA and EMA documents, SEC filings, company press releases, conference abstracts and publications, plus the files your team adds.

  2. One graph

    We link them into one record per company, asset, target, disease and trial, so a readout, a deal and a trial update land in the same place.

  3. Agents

    Each agent runs on a schedule, compares against its last run, and delivers a cited digest, table or one-pager.

  4. Your team reviews

    Every line links to its source. Your team checks it and decides what to use.

Agents by team

Deploy a ready-made agent in one click. Each runs on a schedule and delivers a cited draft for your team to check.

If you run your own agents, they can query Myelin through our API and MCP server.

Competitive & commercial intelligence

Competitor Watch

A Monday digest of what changed for your competitors: trials, data, filings and deals, each cited.

Also: Access Decision Tracker · Trial Change Log

Investors & equity research

Catalyst Calendar

Readouts, filings and PDUFA dates for your watchlist, each with its source and a log of when it moved.

Also: Deck Screen · Filing Changes

Business development & M&A

Deal Comps

Licensing and M&A comps by modality and stage, each disclosed term linked to its source.

Also: Asset Scouting · Partner Mapping

Strategy & consulting

Pipeline Landscape

Every program we find in an indication, by mechanism and stage, with reasons for any left out.

Also: Indication Screen · Client Briefing

Clinical & regulatory

Competing Trials Tracker

Trials recruiting a similar patient population, by country and listed site, with changes flagged weekly.

Also: Protocol Benchmark · Regulatory Precedents

Medical affairs & research

Congress Coverage

Before each congress, the abstracts on your drugs and competitors. After it, a cited recap.

Also: Literature Watch · Target Landscape

Build your own is coming soon: describe the task, choose the sources and set the schedule.

Join the waitlist

Questions first? Read the FAQ.

All fields are required unless marked optional.

For example, a weekly tracker of competitor readouts in NSCLC. Please leave out anything confidential.

By clicking “Join the waitlist,” you agree to our Terms of Use. We’ll use your details to run the waitlist and email you about Myelin, as our Privacy Policy explains. You can opt out anytime.

Built by a team with expertise in agentic solutions and extensive experience across the life sciences

Akash Jain

Co-founder

Formerly at ClearView Healthcare Partners and Headland Strategy Group

Penn M&T, Master’s in Biotechnology

akash@usemyelin.com

Arik Li

Co-founder

Formerly at H.I.G. Capital and Bank of America

Wharton

arik@usemyelin.com